Final Report of the Melanoma Meeting

The international course Melanoma: From Basic Science to Clinical Applications (www.melanoma2015.is), was held in the Harpa Conference Center and Concert Hall, Reykjavik, Iceland, June 24-26, 2015. Major advances in basic research of melanoma have lead to novel treatment options that are making a difference for melanoma patients. However, multiple challenges lie ahead and further progress is necessary, particularly with respect to resistance to the novel therapies. The meeting covered topics ranging from the basic biology and development of the melanocyte to how these cells are transformed into melanoma, and how the disease is diagnosed and treated. A particular emphasis was to bridge the basic and clinical sciences of melanoma and to span the Atlantic divide by bringing American and European melanoma scientists together. Another main issue was to bring together the future leaders in the field.

The meeting was divided into five sessions: (i-ii) Melanocyte and melanoma development 1a and 1b. (ii) Gene regulation in melanocytes and melanoma, (iii) Cell biology to Pathology, (iv) Pathology to Genomics, (v) Clinical advances. One of the lunch breaks was conducted as a separate session termed Luncheon clinical Update and Current Needs.

The meeting was very successful. First, the speakers gave outstanding talks and ample time was allowed for questions and discussions. Second, the frequent coffee breaks and social events allowed further discussions and interactions. And third, the social events, including the Welcome reception, Conference dinner and the trip to the Blue Lagoon further enhanced interactions and discussions. We have received nothing but praise and adulation for the organization of the meeting, its scientific content, the location in Iceland and the friendly and interactive atmosphere we succeeded in creating.

The meeting was attended by a total of 120 people from 17 different countries. The speakers were from both Europe and the US, 14 females and 22 males. They were both established leading investigators and younger speakers selected from abstracts.

Support for the meeting was obtained from various institutions and companies, including Institut Curie, University of Iceland, ESPCR, PASPCR, The French Embassy in Iceland, the Icelandic Cancer Society, University of Colorado Cancer Center, Provectus, Incyte, Amgen, Metabolon, Lytix biopharma, Viralytics and Bristol Myers Squibb. We thank all these organizations for their generous contributions.

The organizers: Lionel LARUE, Eirikur STEINGRIMSSON, Thorunn RAFNAR, Robert ANDTBACKA, Rene GONZALEZ, Karl LEWIS, Caroline ROBERT and Ze’ev RONAI